Cargando…
Cost of epilepsy-related health care encounters in the United States
BACKGROUND: The cost of epilepsy is usually reported as total expenditure over a certain period. However, with the increased availability of acute treatments for use in the community setting, intermittent, single-seizure treatment is now possible in addition to the chronic epilepsy drug treatment pa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390911/ https://www.ncbi.nlm.nih.gov/pubmed/33103619 http://dx.doi.org/10.18553/jmcp.2020.20111 |
_version_ | 1785082581535948800 |
---|---|
author | Borghs, Simon Beaty, Silky Parekh, Witesh Kalilani, Linda Boudiaf, Nada Loewendorf, Andrea |
author_facet | Borghs, Simon Beaty, Silky Parekh, Witesh Kalilani, Linda Boudiaf, Nada Loewendorf, Andrea |
author_sort | Borghs, Simon |
collection | PubMed |
description | BACKGROUND: The cost of epilepsy is usually reported as total expenditure over a certain period. However, with the increased availability of acute treatments for use in the community setting, intermittent, single-seizure treatment is now possible in addition to the chronic epilepsy drug treatment paradigm. Data on the cost of discrete health care encounters are needed to substantiate the cost-benefit of these new treatments. OBJECTIVE: To estimate the health plan-paid costs of discrete epilepsy-related health care encounters in patients with epilepsy. METHODS: This retrospective cohort study utilized IBM MarketScan Commercial Claims, Medicare Supplemental and Coordination of Benefits (Medicare patients with supplemental insurance), and Multi-State Medicaid research databases. The primary analysis determined health plan-paid cost (adjudicated claims) of discrete epilepsy-related health care encounters, defined as having a primary diagnosis code of epilepsy or convulsion, from 2013 to 2018, in patients with epilepsy aged ≥ 12 years. Costs were adjusted to 2018 prices. Epilepsy cases were defined using ICD-CM codes. We excluded patients on capitated insurance plans as their cost per health care encounter is unknown. RESULTS: In total, 353,530 commercially insured, 378,051 Medicaid, and 69,176 Medicare plus supplemental insurance patients with epilepsy were included. More than 160,000 epilepsy-related emergency transportations, 225,000 emergency department (ED) visits, 49,000 hospitalizations, 700 urgent care visits, and ~2.5 million office visits were analyzed. 37.4% of epilepsy-related hospitalizations included care in the intensive care unit (ICU). In commercially insured patients, epilepsy-related health care encounters had median health plan-paid costs of $22,305 (Q1-Q3 = $14,336-$36,096, hospitalization); $3,375 ($565-$9,095, ICU visit); $1,913 ($417-$4,163, ED visit); $687 ($415-$1,083, emergency transportation); $95 ($23-$232, office visit); and $57 ($0-$171, urgent care visit). The median length of stay for epilepsy-related hospitalizations in working age, commercially insured patients was 4 (Q1-Q3 = 2-5) days. CONCLUSIONS: This is the first study to report health plan-paid cost per epilepsy-related health care encounter. These data can serve as a basis for more granular cost-benefit analyses of not only chronic but also acute treatments of epilepsy. |
format | Online Article Text |
id | pubmed-10390911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-103909112023-08-02 Cost of epilepsy-related health care encounters in the United States Borghs, Simon Beaty, Silky Parekh, Witesh Kalilani, Linda Boudiaf, Nada Loewendorf, Andrea J Manag Care Spec Pharm Research Brief BACKGROUND: The cost of epilepsy is usually reported as total expenditure over a certain period. However, with the increased availability of acute treatments for use in the community setting, intermittent, single-seizure treatment is now possible in addition to the chronic epilepsy drug treatment paradigm. Data on the cost of discrete health care encounters are needed to substantiate the cost-benefit of these new treatments. OBJECTIVE: To estimate the health plan-paid costs of discrete epilepsy-related health care encounters in patients with epilepsy. METHODS: This retrospective cohort study utilized IBM MarketScan Commercial Claims, Medicare Supplemental and Coordination of Benefits (Medicare patients with supplemental insurance), and Multi-State Medicaid research databases. The primary analysis determined health plan-paid cost (adjudicated claims) of discrete epilepsy-related health care encounters, defined as having a primary diagnosis code of epilepsy or convulsion, from 2013 to 2018, in patients with epilepsy aged ≥ 12 years. Costs were adjusted to 2018 prices. Epilepsy cases were defined using ICD-CM codes. We excluded patients on capitated insurance plans as their cost per health care encounter is unknown. RESULTS: In total, 353,530 commercially insured, 378,051 Medicaid, and 69,176 Medicare plus supplemental insurance patients with epilepsy were included. More than 160,000 epilepsy-related emergency transportations, 225,000 emergency department (ED) visits, 49,000 hospitalizations, 700 urgent care visits, and ~2.5 million office visits were analyzed. 37.4% of epilepsy-related hospitalizations included care in the intensive care unit (ICU). In commercially insured patients, epilepsy-related health care encounters had median health plan-paid costs of $22,305 (Q1-Q3 = $14,336-$36,096, hospitalization); $3,375 ($565-$9,095, ICU visit); $1,913 ($417-$4,163, ED visit); $687 ($415-$1,083, emergency transportation); $95 ($23-$232, office visit); and $57 ($0-$171, urgent care visit). The median length of stay for epilepsy-related hospitalizations in working age, commercially insured patients was 4 (Q1-Q3 = 2-5) days. CONCLUSIONS: This is the first study to report health plan-paid cost per epilepsy-related health care encounter. These data can serve as a basis for more granular cost-benefit analyses of not only chronic but also acute treatments of epilepsy. Academy of Managed Care Pharmacy 2020-12 /pmc/articles/PMC10390911/ /pubmed/33103619 http://dx.doi.org/10.18553/jmcp.2020.20111 Text en Copyright © 2020, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Brief Borghs, Simon Beaty, Silky Parekh, Witesh Kalilani, Linda Boudiaf, Nada Loewendorf, Andrea Cost of epilepsy-related health care encounters in the United States |
title | Cost of epilepsy-related health care encounters in the United States |
title_full | Cost of epilepsy-related health care encounters in the United States |
title_fullStr | Cost of epilepsy-related health care encounters in the United States |
title_full_unstemmed | Cost of epilepsy-related health care encounters in the United States |
title_short | Cost of epilepsy-related health care encounters in the United States |
title_sort | cost of epilepsy-related health care encounters in the united states |
topic | Research Brief |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390911/ https://www.ncbi.nlm.nih.gov/pubmed/33103619 http://dx.doi.org/10.18553/jmcp.2020.20111 |
work_keys_str_mv | AT borghssimon costofepilepsyrelatedhealthcareencountersintheunitedstates AT beatysilky costofepilepsyrelatedhealthcareencountersintheunitedstates AT parekhwitesh costofepilepsyrelatedhealthcareencountersintheunitedstates AT kalilanilinda costofepilepsyrelatedhealthcareencountersintheunitedstates AT boudiafnada costofepilepsyrelatedhealthcareencountersintheunitedstates AT loewendorfandrea costofepilepsyrelatedhealthcareencountersintheunitedstates |